Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
OIG Gives the OK to Free Genetic Testing & Counseling Arrangement
New OIG Advisory Opinion offers valuable insight into where the agency draws the line on free genetic tests.
Recent Kickback Cases Range from $300 Million Scheme to a Free Service
Of this month’s four Labs in Court cases, three involved kickbacks resulting in widely varying penalties.
Billing & Coding of Outside Pathology Consultations
A briefing of the current requirements you can use to avoid billing and coding errors at your own lab or pathology practice.
Genomic Tests for Prostate Cancer Risk Stratification Are Now Covered
A newly finalized local coverage determination from MAC Palmetto GBA sets out coverage criteria for two applications of these tests.
Review: NIPS Accurate in Detecting Most Common Genetic Abnormalities
A systematic evidence-based review from the ACMG shows NIPS tests are an effective screening tool for general-risk pregnancies.
Apple Employee Uprising Shows Dangers of Ending Remote Work
Lab employees who’ve worked from home may be less than willing to return to the facility, if the situation at Apple is anything to go by.
Plunging Test Rates Threaten Efforts to Detect New SARS-CoV-2 Variants
Despite the emergence and rise of new Omicron variants, COVID-19 testing has declined as much as 90 percent, according to some reports.
Blood-Based Alzheimer’s Tests Have Officially Arrived
Recent developments suggest that we are on the precipice of a new age offering expanded options for Alzheimer’s diagnosis.
Telehealth Encounters Lead to More Follow-Ups than In-Person Visits
Recent study suggests those being treated for acute conditions are likelier to schedule follow-up appointments after telehealth visits.
Medical Device User Fees Agreement Finally Nearing the Finish Line
Though it took longer than expected, the medtech industry and FDA have finally agreed on medical device user fees for the next five years.
